A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)

Interested in this Trial?

Contact Us

Trial Status Terminated

Trial Identifier

NCT02191917

Condition

Late-onset Pompe Disease

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .

Eligibility Criteria

Birth Sex

All

Age

From 18 Years

Healthy Volunteers

No

Drug/Treatment:

Respiratory muscle strength measurements by different techniques.

Study Type:

Observational

Number of Participants:

8

Study Started:

2014-10-21

Study Updated:

2023-01-09

Trial Locations

  • University of Florida

    Gainesville, Florida, United States

  • Royal Brompton Hospital

    London, , United Kingdom

Inclusion Criteria

  • Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures
  • Documented diagnosis with late-onset Pompe disease – At least 18 years of age at study entry
  • Willing and able to comply with all study procedures

Exclusion Criteria

  • Requires ventilatory support while awake and in the upright position
  • Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the investigator, might compromise patient well-being, study completion, or data collection
  • Allergy to tools or procedures used for respiratory muscle testin

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our clinical trials.

By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.

*required fields

"*" indicates required fields

This field is hidden when viewing the form
This field is hidden when viewing the form